Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-01: Volrustomig + Anticancer Agents in Solid Tumors
NCT06448754Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of volrustomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2024; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06448754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448754.